Eli Lilly And Co (NYSE:LLY) was the target of a large drop in short interest in the month of June. As of June 30th, there was short interest totalling 11,502,800 shares, a drop of 8.1% from the May 30th total of 12,512,900 shares. Currently, 1.3% of the company’s stock are sold short. Based on an average trading volume of 4,520,000 shares, the days-to-cover ratio is presently 2.5 days.

Several equities research analysts have commented on the company. ValuEngine lowered WideOpenWest from a “hold” rating to a “sell” rating in a research note on Friday, June 28th. Goldman Sachs Group set a $27.00 price target on Melco Resorts & Entertainment and gave the company a “buy” rating in a research report on Tuesday, May 28th. Barclays restated a “buy” rating and issued a $140.00 price target on shares of Eli Lilly And Co in a research report on Sunday, April 14th. Zacks Investment Research lowered HENGAN INTL GRP/ADR from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, May 21st. Finally, Credit Suisse Group restated a “buy” rating on shares of LVMH Moet Hennessy Louis Vuitton in a research report on Friday, March 22nd. Ten research analysts have rated the stock with a hold rating and eleven have given a buy rating to the company. The stock presently has a consensus rating of “Buy” and a consensus price target of $119.99.

NYSE:LLY traded up $0.18 during trading hours on Monday, reaching $108.47. 4,300,810 shares of the stock were exchanged, compared to its average volume of 10,300,946. The company has a debt-to-equity ratio of 5.50, a current ratio of 1.12 and a quick ratio of 0.85. The stock has a 50-day simple moving average of $114.41. Eli Lilly And Co has a twelve month low of $88.17 and a twelve month high of $132.13. The stock has a market cap of $105.13 billion, a P/E ratio of 19.54, a price-to-earnings-growth ratio of 1.92 and a beta of 0.20.

Eli Lilly And Co (NYSE:LLY) last announced its quarterly earnings data on Tuesday, April 30th. The company reported $1.33 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.32 by $0.01. Eli Lilly And Co had a return on equity of 56.62% and a net margin of 26.13%. The business had revenue of $5.09 billion for the quarter, compared to analysts’ expectations of $5.12 billion. During the same period last year, the firm earned $1.31 earnings per share. The company’s revenue for the quarter was up 2.6% compared to the same quarter last year. As a group, analysts forecast that Eli Lilly And Co will post 5.67 earnings per share for the current fiscal year.

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, September 10th. Shareholders of record on Thursday, August 15th will be paid a $0.645 dividend. This represents a $2.58 dividend on an annualized basis and a yield of 2.38%. The ex-dividend date is Wednesday, August 14th. Eli Lilly And Co’s dividend payout ratio is presently 46.49%.

In other news, SVP Christi Shaw sold 7,577 shares of Eli Lilly And Co stock in a transaction on Friday, May 3rd. The stock was sold at an average price of $117.14, for a total value of $887,569.78. Following the transaction, the senior vice president now directly owns 500 shares in the company, valued at approximately $58,570. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, VP Michael J. Harrington sold 16,000 shares of Eli Lilly And Co stock in a transaction on Monday, June 3rd. The shares were sold at an average price of $116.72, for a total value of $1,867,520.00. Following the completion of the transaction, the vice president now owns 110,300 shares in the company, valued at $12,874,216. The disclosure for this sale can be found here. Company insiders own 0.11% of the company’s stock.

A number of institutional investors have recently bought and sold shares of LLY. Comerica Securities Inc. increased its holdings in shares of Eli Lilly And Co by 80.6% in the 4th quarter. Comerica Securities Inc. now owns 4,154 shares of the company’s stock valued at $481,000 after acquiring an additional 1,854 shares during the period. Tibra Equities Europe Ltd purchased a new position in shares of Eli Lilly And Co in the 4th quarter valued at $2,442,000. Burney Co. increased its holdings in shares of Eli Lilly And Co by 1.9% in the 4th quarter. Burney Co. now owns 123,204 shares of the company’s stock valued at $14,257,000 after acquiring an additional 2,260 shares during the period. Blueshift Asset Management LLC purchased a new position in shares of Eli Lilly And Co in the 4th quarter valued at $1,540,000. Finally, Northern Trust Corp increased its holdings in shares of Eli Lilly And Co by 3.7% in the 4th quarter. Northern Trust Corp now owns 11,638,822 shares of the company’s stock valued at $1,346,844,000 after acquiring an additional 416,787 shares during the period. Institutional investors own 79.39% of the company’s stock.

Eli Lilly And Co Company Profile

Eli Lilly and Company discovers, develops, manufactures, and markets pharmaceutical products worldwide. The company operates in two segments, Human Pharmaceutical Products and Animal Health Products. It offers endocrinology products for the treatment of diabetes; osteoporosis in postmenopausal women and men; and human growth hormone deficiency and pediatric growth conditions.

Recommended Story: Insider Trading – What You Need to Know

Receive News & Ratings for Eli Lilly And Co Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly And Co and related companies with MarketBeat.com's FREE daily email newsletter.